AP
APLIF.US Appili Therapeutics Inc
- Market cap
- USD 265K
- P/E
- -
- P/B
- 1.48x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is APLIF.US undervalued?
Graham numberThe Graham number of Appili Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Appili Therapeutics Inc fundamental analysis
No fundamental analysis for Appili Therapeutics Inc yet.
Appili Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishma…
Full company profileAppili Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Appili Therapeutics Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 199K | 199K | 1.39M | 1.39M | 334K | 827K | 100K | 245K | 281K |
| Gross Profit | -10.5K | -17.7K | -20.7K | 199K | -14.8K | 1.39M | 334K | 827K | 100K | 237K | 276K |
| Operating Income | -3.77M | -3.77M | -7.16M | -4.37M | -16.3M | -23.6M | -7.78M | -2.16M | -191K | -6.55M | -5.97M |
| EBITDA | -3.22M | -6.54M | -6.52M | -5.39M | -15.6M | -23.5M | -8.10M | -2.07M | 361K | -6.54M | -5.97M |
| Net Income | -1.75M | -3.98M | -4.33M | -4.33M | -14.3M | -25.1M | -9.24M | -3.78M | -2.62M | -4.25M | -6.98M |
| EPS | -0.06 | -0.12 | -0.14 | -0.13 | -0.24 | -0.38 | -0.08 | -0.03 | -0.02 | -0.03 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 2.57M | 7.19M | 6.84M | 6.84M | 11.2M | 18.3M | 8.28M | 1.49M | 3.03M | 1.98M | 1.62M |
| Total Liabilities | 1.19M | 2.32M | 2.42M | 2.42M | 2.33M | 5.56M | 11.6M | 12.4M | 16.4M | 19.4M | 22.5M |
| Shareholders' Equity | 1.37M | 4.87M | 4.42M | 4.42M | 8.85M | 12.8M | -3.27M | -10.9M | -13.4M | -17.4M | -20.9M |
| Cash & Short-term Investments | 1.36M | 5.75M | 5.45M | 5.45M | 10.5M | 16.1M | 6.66M | 94.5K | 1.23M | 40.1K | 400K |
| Total Debt | 430K | 1.11M | 1.12M | 1.12M | 1.01M | 1.03M | 4.98M | 8.18M | 12.3M | 13.0M | 13.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.14M | -3.30M | -3.46M | -3.46M | -4.26M | -11.5M | -19.1M | -2.46M | 869K | -1.39M | -1.53M |
| Capital Expenditure | 37.2K | 53.1K | 13.2K | 13.2K | 1.08K | 8.45K | 3.18K | 29.7K | 2.36K | 4.18 | 1.53M |
| Free Cash Flow | -2.17M | -3.36M | -3.47M | -3.47M | -4.26M | -11.5M | -19.1M | -2.49M | 866K | -1.39M | - |
| Ratios | |||||||||||
| ROE | -127.6% | -81.7% | -98.0% | -98.0% | -161.9% | -197.0% | - | - | - | - | - |
| ROA | -68.3% | -55.3% | -63.4% | -63.4% | -128.2% | -137.1% | -111.6% | -253.7% | -86.5% | -214.9% | -431.2% |
| Net Profit Margin | - | - | -2,175.2% | -2,175.2% | -1,030.1% | -1,806.2% | -2,765.9% | -457.0% | -2,613.1% | -1,736.7% | -2,485.8% |
| Debt to Equity | 0.31x | 0.23x | 0.25x | 0.25x | 0.11x | 0.08x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Appili Therapeutics Inc dividends
Appili Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Appili Therapeutics Inc
- Insiders 0.06%
- Institutions 10.85%
- Public & others 89.10%
- Shares outstanding 132M
- Free float 118M
Appili Therapeutics Inc company profile
- Company name
- Appili Therapeutics Inc
- Ticker
- APLIF.US
- ISIN
- CA03783R1073
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- March
- Address
- 1344 Summer Street, Halifax, NS, Canada, B3H 0A8
- Phone
- 902-442-4655
- Website
- appilitherapeutics.com
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc management
6- Dr. Donald D. Cilla Jr., M.B.A., PharmdCEO, President & Director
- Mr. Kenneth G. HowlingActing Chief Financial Officer · born 1958
- Dr. Gary S. Nabors Ph.D.Chief Development Officer
- Dr. Carl Gelhaus Ph.D.Director of Non-Clinical Research
- Mr. Arthur BaranDirector of New Product Development
- Jenna McNeilCorporate Affairs & Communications Manager